Moderna shares rose 6.98% to $194.82 on Thursday after chairman Noubar Afeyan met UAE Minister of State Saeed bin Mubarak Al Hajeri to discuss investment and cooperation in advanced pharmaceuticals; the stock reached $195.71 intraday.
The meeting covered research and development, sharing expertise and strengthening UAE pharmaceutical manufacturing. The report describes investment opportunities under discussion, not a finalized deal, and links the talks to the U.S.-UAE strategic partnership.
Investors were also awaiting updated data from Moderna and Merck’s Phase 3 INTerpath-001 trial of intismeran autogene with Keytruda. Results were due at the ESMO Congress in Madrid, October 23–27, 2026; the article says the trial met its primary recurrence-free-survival endpoint and key secondary distant-metastasis-free-survival target. In the second quarter, 49 hedge funds held Moderna shares, down from 52, while their combined holdings rose 10% to $1.5 billion, according to Insider Monkey.
